1054315-48-8 Usage
General Description
BMS 695735 is a chemical compound developed by Bristol-Myers Squibb for potential use in the treatment of cancer. It belongs to the class of PI3K inhibitors, which work by blocking the activity of the phosphoinositide 3-kinase (PI3K) enzyme. This enzyme plays a role in cell growth, proliferation, and survival, and is often dysregulated in cancer cells. By inhibiting PI3K, BMS 695735 has the potential to halt the growth and spread of cancer cells, making it a promising candidate for targeted cancer therapy. Studies have shown that BMS 695735 is effective in inhibiting the growth of tumor cells in preclinical models, and it is currently being investigated in clinical trials for its safety and efficacy in patients with various types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1054315-48-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,5,4,3,1 and 5 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1054315-48:
(9*1)+(8*0)+(7*5)+(6*4)+(5*3)+(4*1)+(3*5)+(2*4)+(1*8)=118
118 % 10 = 8
So 1054315-48-8 is a valid CAS Registry Number.
1054315-48-8Relevant articles and documents
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3- (6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl) pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kin
Velaparthi, Upender,Wittman, Mark,Liu, Peiying,Carboni, Joan M.,Lee, Francis Y.,Attar, Ricardo,Balimane, Praveen,Clarke, Wendy,Sinz, Michael W.,Hurlburt, Warren,Patel, Karishma,Discenza, Lorell,Kim, Sean,Gottardis, Marco,Greer, Ann,Li, Aixin,Saulnier, Mark,Yang, Zheng,Zimmermann, Kurt,Trainor, George,Vyas, Dolatrai
supporting information; experimental part, p. 5897 - 5900 (2009/10/09)
We previously reported that 1 (BMS-536924), a benzimidazole inhibitor of the insulin-like growth factor-1 receptor, had demonstrated in vivo antitumor activity. This lead compound was found to have potent CYP3A4 inhibition, CYP3A4 induction mediated by PX
